Each year, the LSX World Congress gathers the brightest minds and boldest innovators across the life‐sciences ecosystem. From Biotech to Medtech to the emerging frontier of Pharmatech, this year’s event once again positions itself as a global hub for strategy, investment, and partnership, where the conversations today define the breakthroughs of tomorrow.

Pharmatech: The Fusion of Pharma and Digital Innovation

This year marks the expansion of LSX into pharmatech, a dedicated track designed to bridge the gap between pharma executives and digital‐health technology providers.

“Pharmatech is a track that we've added in, to bring together pharma executives and digital health technology providers. We hope to bring them together for knowledge sharing and discussions around how pharma is using AI and other technologies.’’

“We have a vast number of companies attending our event, and we have worked hard to increase the content available to them to maximise their value at the event.” – Nadia Moodie, Portfolio Manager, LSX World Congress

Here are two standout sessions in this track:

• “The Investment Blueprint: Funding Strategies for Pre-Market Medtech Companies in a Challenging Environment” – Although labelled under medtech, the themes of digital funding, early-stage tech and strategic investor expectations crossover strongly into pharmatech.

The pharmatech track now provides a platform for those working at the crossroads of AI, data‐driven clinical development, and next-generation drug discovery — a clear sign of how digital transformation is reshaping the pharmaceutical landscape.

Biotech: Capital, Collaboration and Commercialisation

The biotech leaders track remains a cornerstone of the LSX agenda, drawing executives, investors and dealmakers from across the globe.

“The biotech leaders track covers three main pillars of content. That’s capital markets and investment, partnerships and deal making, and commercialization and market opportunities, anything that a biotech could be looking to learn about.”

“I think with the current market dynamics and climate, and especially the oncoming patent cliff, the agenda really is designed to equip both biotechs and pharmaceutical companies about anything from raising capital to doing deals.”

“I think what people will get out of the programme are strategic insights, unique case studies and newsworthy stories that you cannot find anywhere else.”- Adam Griffiths, Portfolio Manager, LSX World Congress

Highlighted sessions include:

• “Assessing Biotech Investment Trends in 2026 & Beyond” – A morning keynote exploring how biotech companies can reposition themselves in a shifting market.
• “Investment, Innovation, and Influence: Reimagining Europe’s Role in Global Life Sciences” – This panel asks important questions such as how biotech companies can adjust valuations, how investors are rethinking value creation, and how pharma is seizing new partnership opportunities.

From panel discussions on financing early‐stage biotech ventures to fireside chats with major pharma leaders, the track delivers strategic insights, unique case studies and newsworthy stories you cannot find anywhere else.

Attendees leave not only with investment strategies but also real-world frameworks for commercialization, a crucial focus as biotechs transition from discovery to delivery.

Medtech: Solving Industry Challenges and Accelerating Growth

If biotech is about capital and science, medtech is about translating innovation into patient impact. The medtech track at LSX focuses on practical solutions and leadership strategies for growth-stage companies.

“This year’s agenda convenes subject matter experts and tier 1 executives to discuss and solve medtech’s biggest challenges and unlock new opportunities. The discussions will feature case studies and insights from boots on the ground medtech leaders, providing valuable and actionable solutions for medtech companies at all stages of growth. Join us to gain the strategies, insights, and connections needed to drive innovation, accelerate growth, and shape the future of medtech.” – Jack Giles, Conference Producer, LSX World Congress

Key sessions include:

• “The Investment Blueprint: Funding Strategies for Pre-Market Medtech Companies in a Challenging Environment” – A panel dissecting how early-stage medtech companies can navigate funding contraction, alternative sources of capital, and strategic partnerships.

The session spotlights key themes including scaling manufacturing, regulatory navigation, and strategic partnerships for market entry, all framed by the shared mission to empower medtech innovators to move faster and smarter.

Connecting the Dots Across Life Sciences

What makes LSX unique is how it breaks down the silos between disciplines. The integration of pharmatech, medtech and biotech under one roof allows leaders to explore the intersections where digital tools, biological innovation and device technology converge.

For investors, it’s a snapshot of where healthcare’s next major opportunities lie. For startups, it’s a chance to meet collaborators who can transform ideas into impact. And for the global healthcare community, it’s a preview of how the future of medicine will be built, one partnership at a time.